Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed ...

Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S.

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Daiichi Sankyo today announced the appointment of Hiroyuki Okuzawa as its new global Chief Executive Officer (CEO), effective April 1, 2025. Mr. Okuzawa who currently serves as Representative ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. $350M ...

Let me introduce today's speakers, Okuzawa, Representative Director, President and CEO; Ogawa, Senior Executive Officer and CFO; and Takeshita, Head of Global R&D. First, Okuzawa and Takeshita ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP. AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the ...